vs
Brown & Brown（BRO）与德康医疗（DXCM）财务数据对比。点击上方公司名可切换其他公司
Brown & Brown的季度营收约是德康医疗的1.3倍（$1.6B vs $1.3B），德康医疗净利率更高（21.2% vs 16.5%，领先4.7%），Brown & Brown同比增速更快（35.8% vs 21.6%），过去两年Brown & Brown的营收复合增速更高（13.0% vs 12.0%）
Brown & Brown是总部位于美国佛罗里达州代托纳比奇的保险经纪公司，是美国规模最大的独立保险中介机构之一，面向企业、政府机构、专业组织、行业协会及个人客户提供风险管理解决方案、保险产品及相关服务。
德康医疗是美国跨国医疗保健企业，专注于研发、生产及销售糖尿病管理领域的连续血糖监测（CGM）系列系统。其全球总部及研发中心位于美国加利福尼亚州圣地亚哥，生产基地分布于美国亚利桑那州梅萨、马来西亚峇都交湾及爱尔兰戈尔韦郡阿斯里。
BRO vs DXCM — 直观对比
营收规模更大
BRO
是对方的1.3倍
$1.3B
营收增速更快
BRO
高出14.3%
21.6%
净利率更高
DXCM
高出4.7%
16.5%
两年增速更快
BRO
近两年复合增速
12.0%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $1.6B | $1.3B |
| 净利润 | $265.0M | $267.3M |
| 毛利率 | — | 62.9% |
| 营业利润率 | — | 25.6% |
| 净利率 | 16.5% | 21.2% |
| 营收同比 | 35.8% | 21.6% |
| 净利润同比 | 26.8% | 153.6% |
| 每股收益（稀释后） | $0.55 | $0.67 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BRODXCM
| Q1 26 | — | $1.3B | ||
| Q4 25 | $1.6B | $1.3B | ||
| Q3 25 | $1.6B | $1.2B | ||
| Q2 25 | $1.3B | $1.2B | ||
| Q1 25 | $1.4B | $1.0B | ||
| Q4 24 | $1.2B | $1.1B | ||
| Q3 24 | $1.2B | $994.2M | ||
| Q2 24 | $1.2B | $1.0B |
净利润BRODXCM
| Q1 26 | — | $267.3M | ||
| Q4 25 | $265.0M | $267.3M | ||
| Q3 25 | $227.0M | $283.8M | ||
| Q2 25 | $231.0M | $179.8M | ||
| Q1 25 | $331.0M | $105.4M | ||
| Q4 24 | $209.0M | $151.7M | ||
| Q3 24 | $234.0M | $134.6M | ||
| Q2 24 | $257.0M | $143.5M |
毛利率BRODXCM
| Q1 26 | — | 62.9% | ||
| Q4 25 | — | 62.9% | ||
| Q3 25 | — | 60.5% | ||
| Q2 25 | — | 59.5% | ||
| Q1 25 | — | 56.9% | ||
| Q4 24 | — | 58.9% | ||
| Q3 24 | — | 59.7% | ||
| Q2 24 | — | 62.4% |
营业利润率BRODXCM
| Q1 26 | — | 25.6% | ||
| Q4 25 | — | 25.6% | ||
| Q3 25 | — | 20.1% | ||
| Q2 25 | — | 18.4% | ||
| Q1 25 | — | 12.9% | ||
| Q4 24 | 23.3% | 17.0% | ||
| Q3 24 | 26.7% | 15.3% | ||
| Q2 24 | 29.4% | 15.7% |
净利率BRODXCM
| Q1 26 | — | 21.2% | ||
| Q4 25 | 16.5% | 21.2% | ||
| Q3 25 | 14.1% | 23.5% | ||
| Q2 25 | 18.0% | 15.5% | ||
| Q1 25 | 23.6% | 10.2% | ||
| Q4 24 | 17.7% | 13.6% | ||
| Q3 24 | 19.7% | 13.5% | ||
| Q2 24 | 21.8% | 14.3% |
每股收益（稀释后）BRODXCM
| Q1 26 | — | $0.67 | ||
| Q4 25 | $0.55 | $0.67 | ||
| Q3 25 | $0.68 | $0.70 | ||
| Q2 25 | $0.78 | $0.45 | ||
| Q1 25 | $1.15 | $0.27 | ||
| Q4 24 | $0.73 | $0.37 | ||
| Q3 24 | $0.81 | $0.34 | ||
| Q2 24 | $0.90 | $0.35 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.1B | $917.7M |
| 总债务越低越好 | $7.6B | — |
| 股东权益账面价值 | $12.6B | $2.7B |
| 总资产 | $30.0B | $6.3B |
| 负债/权益比越低杠杆越低 | 0.61× | — |
8季度趋势，按日历期对齐
现金及短期投资BRODXCM
| Q1 26 | — | $917.7M | ||
| Q4 25 | $1.1B | $917.7M | ||
| Q3 25 | $1.2B | $1.8B | ||
| Q2 25 | $8.9B | $1.2B | ||
| Q1 25 | $669.0M | $904.9M | ||
| Q4 24 | $685.0M | $606.1M | ||
| Q3 24 | $968.0M | $621.2M | ||
| Q2 24 | $1.1B | $939.2M |
总债务BRODXCM
| Q1 26 | — | — | ||
| Q4 25 | $7.6B | — | ||
| Q3 25 | $7.7B | — | ||
| Q2 25 | $7.5B | — | ||
| Q1 25 | $3.8B | — | ||
| Q4 24 | $3.8B | — | ||
| Q3 24 | $3.6B | — | ||
| Q2 24 | $4.1B | — |
股东权益BRODXCM
| Q1 26 | — | $2.7B | ||
| Q4 25 | $12.6B | $2.7B | ||
| Q3 25 | $12.4B | $2.7B | ||
| Q2 25 | $11.6B | $2.6B | ||
| Q1 25 | $6.8B | $2.3B | ||
| Q4 24 | $6.4B | $2.1B | ||
| Q3 24 | $6.5B | $2.0B | ||
| Q2 24 | $6.0B | $2.4B |
总资产BRODXCM
| Q1 26 | — | $6.3B | ||
| Q4 25 | $30.0B | $6.3B | ||
| Q3 25 | $29.4B | $7.5B | ||
| Q2 25 | $25.6B | $7.3B | ||
| Q1 25 | $16.8B | $6.8B | ||
| Q4 24 | $17.6B | $6.5B | ||
| Q3 24 | $17.5B | $6.4B | ||
| Q2 24 | $15.9B | $6.8B |
负债/权益比BRODXCM
| Q1 26 | — | — | ||
| Q4 25 | 0.61× | — | ||
| Q3 25 | 0.62× | — | ||
| Q2 25 | 0.65× | — | ||
| Q1 25 | 0.56× | — | ||
| Q4 24 | 0.59× | — | ||
| Q3 24 | 0.55× | — | ||
| Q2 24 | 0.68× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $444.0M | — |
| 自由现金流经营现金流 - 资本支出 | $424.0M | — |
| 自由现金流率自由现金流/营收 | 26.4% | — |
| 资本支出强度资本支出/营收 | 1.2% | — |
| 现金转化率经营现金流/净利润 | 1.68× | — |
| 过去12个月自由现金流最近4个季度 | $1.4B | — |
8季度趋势，按日历期对齐
经营现金流BRODXCM
| Q1 26 | — | — | ||
| Q4 25 | $444.0M | $294.0M | ||
| Q3 25 | $468.0M | $659.9M | ||
| Q2 25 | $325.0M | $303.0M | ||
| Q1 25 | $213.0M | $183.8M | ||
| Q4 24 | $361.0M | $301.4M | ||
| Q3 24 | $440.0M | $199.5M | ||
| Q2 24 | $360.0M | $279.4M |
自由现金流BRODXCM
| Q1 26 | — | — | ||
| Q4 25 | $424.0M | $192.1M | ||
| Q3 25 | $452.0M | $579.4M | ||
| Q2 25 | $310.0M | $208.9M | ||
| Q1 25 | $196.0M | $96.8M | ||
| Q4 24 | $341.0M | $176.8M | ||
| Q3 24 | $417.0M | $88.3M | ||
| Q2 24 | $334.0M | $213.3M |
自由现金流率BRODXCM
| Q1 26 | — | — | ||
| Q4 25 | 26.4% | 15.3% | ||
| Q3 25 | 28.1% | 47.9% | ||
| Q2 25 | 24.1% | 18.1% | ||
| Q1 25 | 14.0% | 9.3% | ||
| Q4 24 | 28.8% | 15.9% | ||
| Q3 24 | 35.2% | 8.9% | ||
| Q2 24 | 28.4% | 21.2% |
资本支出强度BRODXCM
| Q1 26 | — | — | ||
| Q4 25 | 1.2% | 8.1% | ||
| Q3 25 | 1.0% | 6.7% | ||
| Q2 25 | 1.2% | 8.1% | ||
| Q1 25 | 1.2% | 8.4% | ||
| Q4 24 | 1.7% | 11.2% | ||
| Q3 24 | 1.9% | 11.2% | ||
| Q2 24 | 2.2% | 6.6% |
现金转化率BRODXCM
| Q1 26 | — | — | ||
| Q4 25 | 1.68× | 1.10× | ||
| Q3 25 | 2.06× | 2.33× | ||
| Q2 25 | 1.41× | 1.69× | ||
| Q1 25 | 0.64× | 1.74× | ||
| Q4 24 | 1.73× | 1.99× | ||
| Q3 24 | 1.88× | 1.48× | ||
| Q2 24 | 1.40× | 1.95× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BRO
| US | $1.4B | 87% |
| GB | $147.0M | 9% |
| Profit Sharing Contingent Commission Revenue | $33.0M | 2% |
| Other Supplemental Commissions Revenue | $25.0M | 2% |
DXCM
暂无分部数据
